



RAPID ALERT

DRAP ALERT No: I/S/9-24-35

CRACKDOWN AGAINST FALSIFIED DRUG PRODUCTS.

Date: 24th September, 2024.

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public

Alert Summary:

The Directorate of Drugs Control (DDC) Punjab has detected the following falsified drug products based on their analysis from Drug Testing Laboratories (DTLs). The details of identified products and their batch details are as under:

S#	Product Name	Composition	Batch No.	Manufactured by (as per label)	Test Results
01	Solveron 10mg Tablets	Dydrogesterone 10mg	SVN-001	M/s. Solvay, Plot# 32, Sector 2, Highway Petaro Road, Jamshoro.	Spurious
02	Carenol Syrup 450ml	Ammonium chloride 125mg/5ml, Sodium Citrate 55mg/5ml, Chlorpheniramine Maleate 2.5mg/5ml	CL-012	M/s. Well Care Pharmaceuticals, A/7 P.S.I.E. Sargodha.	Spurious and Misbranded
03	Procain Penicillin Fort 4000000 I.U. Injection	Procaine Penicillin 3000000 I.U., Benzyl Penicillin 1000000 I.U.	140475	M/s. Yanzhou Xier Kangtai Pharm. Co. Ltd., China. Sole agent: United International, 301 Madian Center, Plot No. MR-1/122, 3 rd Floor, Kutchi Gali No. 2, Marriot Road, Karachi.	Spurious
04	Simgesic Film Coated Tablet	Tramadol HCl 37.5mg, Paracetamol 325mg	B1985	M/s. Siam Pharmaceutical, Plot No. 217, Industrial Triangle, Kahuta Road, Islamabad.	Spurious and Misbranded
05	Meronem 500mg Injection	Meropenem 500mg	4B23D121	ACS Dobfar S.p.A Viale Addetta 4/12, Tribiano, Milan Italy.	Spurious and Substandard
06	Meronem 1g Injection	Meropenem 1gm	4A23A31	Packed and Marketed by: Pfizer Pakistan Limited Karachi.	

Note: The red color font in the table indicates fake products and manufacturers' names. These are not licensed or registered by DRAP.





Risk Statement:

Spurious/falsified pharmaceuticals may contain harmful levels of toxic substances, which pose a significant risk and can undermine the effectiveness of disease treatment. They may also worsen preexisting medical conditions. The safety and quality of the counterfeit products mentioned in this alert are unknown.

Action initiated:

The regulatory field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection and removal of these products from the market. All pharmacists and chemists working at distributions and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and the information of their supplier should be immediately provided to their area drug inspectors to ensure the removal of falsified product.

Advice for Healthcare Professionals:

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this [link](#). Further information of reporting problems to DRAP is available on this [link](#).

Advice for Consumers / general public:

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan

محفوظ، مونٹر اور معیاری اشیائے علاج



DRAP, Islamabad



+ 92 051 9255969



gsms@dra.gov.pk